Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results, Misses Estimates By $0.02 EPS

Posted by Geri Gentry on May 16th, 2026

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02), FiscalAI reports. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.38 million.

Here are the key takeaways from Lucid Diagnostics’ conference call:

Lucid Diagnostics said first-quarter EsoGuard testing volume was 3,177 tests, above its pre-Medicare target range, and revenue of $1.3 million was broadly in line with the lower volume.
The company raised about $16.8 million in an underwritten offering, ending Q1 with $44.8 million in pro forma cash and saying the runway extends well into 2027.
Management reiterated that the Medicare LCD process is delayed by logistics rather than substance and said it remains highly confident a positive decision will come in the near term.
Lucid highlighted early progress in the VA system, including its first purchase order and expectations to begin testing and generating revenue soon, with reimbursement at the Medicare-rate equivalent under the Federal Supply Schedule.
The company also pointed to expanding commercial payer and LBM coverage, including its first not-yet-public coverage policy from a laboratory benefit manager and encouraging feedback from payers referencing EsoGuard as a triage test.

Lucid Diagnostics Trading Down 2.8%

Shares of NASDAQ LUCD traded down $0.03 during trading hours on Friday, reaching $0.99. The stock had a trading volume of 1,375,486 shares, compared to its average volume of 866,211. The firm has a market cap of $193.52 million, a price-to-earnings ratio of -2.11 and a beta of 1.10. Lucid Diagnostics has a fifty-two week low of $0.95 and a fifty-two week high of $1.70. The firm has a 50-day moving average of $1.20 and a 200-day moving average of $1.18.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, March 26th. Finally, BTIG Research reiterated a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a report on Friday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.13.

Read Our Latest Analysis on LUCD

Institutional Trading of Lucid Diagnostics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Lucid Diagnostics by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock valued at $4,569,000 after purchasing an additional 396,719 shares during the period. Masters Capital Management LLC lifted its position in Lucid Diagnostics by 46.6% during the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after acquiring an additional 1,272,000 shares during the period. Two Seas Capital LP acquired a new stake in Lucid Diagnostics during the 3rd quarter worth approximately $3,030,000. Geode Capital Management LLC lifted its position in Lucid Diagnostics by 21.1% during the 4th quarter. Geode Capital Management LLC now owns 2,026,827 shares of the company’s stock worth $2,209,000 after acquiring an additional 352,654 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in Lucid Diagnostics by 87.3% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,383,116 shares of the company’s stock worth $1,397,000 after acquiring an additional 644,839 shares during the period. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.